Curated news and analysis on clinical trials, drug approvals, and medical research.
BIIB122 failed to slow Parkinson's progression in the Phase 2b LUMA study, missing primary and secondary endpoints. Biogen and Denali will discontinue the drug in idiopathic Parkinson's disease; Denali continues the BEACON study in LRRK2 carriers.
New Zealand’s health agency remains non-compliant with an Ombudsman’s order to resume publishing national harm reports, while Arizona and Florida propose legislation mandating serious adverse event reporting by medical spas within five business days.
InnoCare's TYK2 inhibitor fadeucravacitinib met primary and secondary endpoints in a Phase 3 psoriasis trial, with a favorable safety profile. InnoCare plans to seek regulatory approval.
At ESMO GI 2026, the GALAXY study showed ctDNA tests can identify colorectal cancer patients who benefit from adjuvant chemotherapy. A separate study found CLK3 regulates colorectal tumor angiogenesis by stabilizing HIF1α.
KEYNOTE-942 five-year data: intismeran autogene plus Keytruda reduced melanoma recurrence risk by 49% and kept 68.8% of patients cancer-free versus 49.1% with Keytruda alone. Distant metastasis or death risk fell 59%.
Rising Pharma Holdings Inc. recalls four lots of 5 mg cetirizine hydrochloride allergy tablets after a pharmacy tech noticed possible cross-contamination with ranitidine, posing life-threatening risks to hypersensitive individuals.
FDA approved AstraZeneca's Breztri Aerosphere for asthma; EU CHMP recommended Trixeo. Phase 3 KALOS/LOGOS trials showed improved lung function and reduced severe exacerbations versus dual therapy.
Presenters at the 2026 ICE-T Conference discussed the growing role of bispecific antibodies and CAR T-cell therapies in hematologic cancers, while a separate study found that structural instability of linkers in symmetric bispecific antibodies could pose manufacturing hurdles.
The Bundibugyo Ebola outbreak in the DRC has surpassed 3,200 cases and 1,400 deaths, becoming the fastest-spreading Ebola outbreak ever. The first-ever Bundibugyo-specific vaccine trial has begun at Oxford, while healthcare workers at the epicenter have gone on strike over unpaid wages. The WHO has declared the outbreak a global health emergency.
AstraZeneca Q2 core EPS of $2.63 beat consensus, driven by 15% oncology and 8% rare disease growth. The company maintained its 2030 $80 billion revenue target and has more than 20 Phase III readouts expected over the next 18 months.
The U.S. FDA approved Nuzolvence (zoliflodacin), a single-dose oral treatment for uncomplicated urogenital gonorrhea, based on a non-inferiority Phase 3 trial. Thailand also authorized the drug under the brand Nuzolvance, expanding access in low- and middle-income countries.
A prototype smart ring tracks multiple metabolic biomarkers in sweat, while Amazon One Medical launches Health Insights for blood biomarker analysis. Pharmacies are also using point-of-care testing to personalize supplement recommendations.
Genomic medicine market is projected to reach USD 123 billion by 2035; AI in genomics USD 6.5 billion; viral vector manufacturing USD 15.83 billion. Gene therapy trials drive growth.
Trump’s phased tariffs on medicines spur over $400 billion in US pharma investments. Indian generic makers face a 2028 deadline to adapt.
NEXT BIOMEDICAL completed an FDA pre-submission review for Nexsphere-F under the TAP program. NexEos Bio received IND clearance to begin a Phase II/III trial of NTX-1024 for vernal keratoconjunctivitis, supported by positive early clinical data.
Ultragenyx cuts 10% of staff after setrusumab Phase III misses; VERAXA Biotech shareholders approve capital and board changes at EGM.
Novartis beat second-quarter profit expectations as Kisqali, Kesimpta and Leqvio offset a 50% plunge in Entresto sales. The Swiss drugmaker maintained its full-year guidance and awaits late-stage data on three experimental drugs.
A newly reported antimicrobial peptide, GT-2, selectively disrupts microbial membranes while sparing mammalian cells. The peptide adopts a helical conformation in response to bacterial and fungal lipids and reduced Pseudomonas aeruginosa wound burden below the detection limit in a topical model.
Ultragenyx granted 65,886 RSUs to 39 new non-executive officers in July 2026 and reported similar inducement grants in April, May, and June 2026. Awards vest over four years.
New research and guidelines highlight the promise and perils of AI in medicine, from a Dartmouth study showing AI-drafted patient messages can introduce errors, to the Israel Medical Association's new position paper. Regulatory responses vary, with FDA guidance and state laws still evolving.
